The clinical setback centers on the FURVENT study, which evaluated firmonertinib as a first-line treatment for patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer. Following the failure to reach the primary endpoint of progression-free survival, shares of the NASDAQ-listed firm faced intense volatility, sinking between 50% and 63% during regular trading hours. This decline arrives just five months after ArriVent secured $250 million through an at-the-market stock offering in May 2026, a period during which the firm described the trial as ongoing.
Legal firm Levi & Korsinsky has launched an investigation into potential securities law violations. The inquiry seeks to determine whether ArriVent provided misleading statements regarding the status and prospects of its pivotal clinical program. Investors who purchased stock at allegedly inflated prices are being encouraged to submit brokerage records for a recovery evaluation, regardless of whether they still hold their shares or have already realized losses.
Comments (0)
No comments yet. Be the first!